![Page 1: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/1.jpg)
The Rising Prevalence of NCDs: Implications for Health Financing and
Policy
Charles Holmes, MD, MPHOffice of the U.S. Global AIDS
CoordinatorDepartment of State
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 2: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/2.jpg)
Objectives
1. Examine the economic impacts of NCDs in LMIC, and what we know and don’t know about the costs of developing a robust NCD response.
2. Explore what we have learned from the HIV financing response and to consider how the NCD response can be earlier adopters of these methods moving forward.
3. To highlight policy and other financing issues that are essential to continuing to build strong HIV and NCD responses
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 3: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/3.jpg)
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Health and Economic Impacts of NCDs
• NCD rates are nearly two-times higher in low- and middle-income countries then in high-income countries• 250 million deaths and $84 billion of lost national output from 2006-2015 in 23 low- and middle-income countries• Household effects:
– Out of pocket expenses for treatment range from 4 to 34% of household income/expenditures
– Decreased earnings– Increased healthcare expenditures including
• Catastrophic expenditures for NCDs in up to 20% of affected households
![Page 4: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/4.jpg)
Estimated Cost Categoriesfor CVD Prevention Package
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Lim et al, Lancet 2007
![Page 5: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/5.jpg)
Average Annual Cost for an NCD Response
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Lim et al, Lancet 2007
![Page 6: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/6.jpg)
Theoretical CVD Response as a Proportion of Health Expenditure
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Lim et al, Lancet 2007
![Page 7: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/7.jpg)
Lower Costs of “Upstream” Interventions in LMIC
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 8: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/8.jpg)
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Donor Funding for Health
![Page 9: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/9.jpg)
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 10: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/10.jpg)
Leveraging Available Resources
“Every dollar spent by PEPFAR on [our] Medical Record System to control HIV was also spent on NCD control.
In a similar vein, PEPFAR dollars that were spent to strengthen communications, monitoring and evaluation,
transportation system, data management, pharmacy, and supply chain, in order to control HIV, are also
relevant to the control of other chronic diseases like cardiovascular disease, hypertension, and diabetes.”
-PEPFAR Implementing Partner
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 11: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/11.jpg)
LESSONS LEARNED FROM THE HIV FINANCING RESPONSE
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 12: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/12.jpg)
Development and Use of Empiric Cost Data
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
2010 PEPFAR Congressional Report
![Page 13: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/13.jpg)
Note: Per-patient PEPFAR budget allocation is estimated as lagged treatment allocation divided by end-of-reporting of patients directly supported on ART by PEPFAR. Budget per result estimates may vary from site-level costing estimates.
Declining HIV Treatment Costs under PEPFAR, 2004-2009
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 14: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/14.jpg)
Use of Expenditure Analysis
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 15: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/15.jpg)
Creative Financing
• Private sector programs will fill an important niche
• Opportunity for risk sharing through insurance and other mechanisms
• Leveraging existing health platforms
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 16: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/16.jpg)
Expanded NSP Treatment Costs, South Africa
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
aids2031
![Page 17: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/17.jpg)
OTHER POLICY ISSUES
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 18: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/18.jpg)
Country Ownership and Stakeholder Collaboration
• National strategies are helpful
• Opportunity to define roles for country governments, and other partners
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 19: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/19.jpg)
Country Ownership and Stakeholder Collaboration
• 21 PEPFAR Partnership Frameworks signed– 5-year joint strategic frameworks for collaboration on HIV/AIDS
– Service delivery – Policy reform– Financing
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
![Page 20: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/20.jpg)
Building on Existing Platforms: A Need for Both Marginal Effectiveness and Costs
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome
Detection of HIV among TB Suspects in Rwanda (2009 – 2010)
![Page 21: The Rising Prevalence of NCDs: Implications for Health Financing and Policy Charles Holmes, MD, MPH Office of the U.S. Global AIDS Coordinator Department](https://reader030.vdocuments.site/reader030/viewer/2022032607/56649eca5503460f94bd825a/html5/thumbnails/21.jpg)
Applying Lessons Going Forward
• Be Efficient from the Start: Identify and target key drivers of the NCD response cost early and conduct special studies be efficient from the start.
• Use Cost Data: Develop methods for generating and using cost data as standard monitoring and evaluation data points, and expand beyond unit costs of treatment.
• Country Owned and Multiple Funding Sources: Ensuring that the response is country owned and defined through national health strategies, assisting in the coordination of multiple sources of funding, including governments, donors, and private sector and risk pooling.
• Marginal Costs and Effectiveness of Integration
HIV and Non-communicable Diseases Pre-Conference,
July 15-16, 2011, Rome